EUDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EUDA Health Holdings Ltd is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical strength, but the bigger picture is weak: the latest analyst target was cut sharply to $2.75 from $6, Nasdaq issued a compliance notice for minimum market value, and insider/hedge fund activity is neutral. Since there is no strong proprietary buy signal today and the user wants a direct answer without waiting for a better entry, the clear call is to hold off rather than buy now.
Technically, EUDA is in a short-term bullish phase but not an attractive long-term entry. MACD histogram is positive and expanding, which supports near-term momentum. However, RSI_6 at 79.482 shows the stock is overbought, and the moving averages are only converging rather than confirming a strong sustained uptrend. The stock closed at 13.9253 after a prior close of 14.53, with mixed after-hours weakness. The pivot at 13.383 is close to current price, while resistance sits far above at 20.923. Overall, the chart suggests momentum exists, but the setup is stretched and not ideal for a beginner long-term buyer.
["Shenzhen Inno received approval for a Shenzhen R&D project, securing about $434,688 in funding for TCR-T therapy development.", "MACD histogram is positive and expanding, indicating near-term momentum.", "The stock is trading above its pivot level, which supports the current trend."]
["Nasdaq notified the company of non-compliance with the Minimum Market Value of Listed Securities, creating delisting risk if compliance is not regained within 180 days.", "Analyst price target was cut sharply to $2.75 from $6, reflecting weaker expectations.", "The reduced Helixe bottle sales estimate and added 12.5M shares issued in late February imply lower revenue and dilution pressure.", "Insiders and hedge funds show no meaningful bullish accumulation trend.", "RSI is elevated at 79.482, suggesting the stock is already extended."]
No usable latest-quarter financial snapshot was provided, so the company’s most recent quarter growth trends cannot be assessed from the data supplied. The only financial-related update available is analyst-driven: Greenridge lowered 2026 revenue expectations to $27.23M from $43.05M after reducing Helixe bottle sales assumptions and accounting for share dilution. That points to softer forward growth expectations rather than improving fundamentals.
Wall Street remains split but less optimistic than before. Greenridge kept a Buy rating, but slashed its price target to $2.75 from $6, which is a bearish revision in expectations despite the formal Buy label. The pros view is that the business still has speculative upside and an active development pipeline, while the cons view is that revenue assumptions were reduced, dilution has increased, and Nasdaq compliance risk weighs heavily on the stock.
